Replies to post #15699 on Momenta Pharmaceuticals, Inc. (MNTA)

[DewDiligence]

MNTA continues to have strong liquidity:

https://www.sec.gov/Archives/edgar/data/1235010/000123501016000008/mnta0630201610q.htm#s0BCA1FD2CD8E594D92231793B023C9C1

The 6/30/16 pro forma cash balance was $369.7M; this consisted of: $336.9M of unrestricted cash and marketable securities; $35.9M of collaboration receivables from MYL relating to the companies’ FoB partnership; $20.7M of restricted cash (mostly related to the Lovenox patent case); less $23.8 in net current liabilities.

For the remainder of 2016, MNTA’s cash-usage guidance—excluding all revenue from NVS and SHPG, but taking into account R&D reimbursement from MYL—is $40-45M per quarter.